VERV’s VERVE-102 showed an impressive 69% LDL-C reduction in its early Phase 1b data. Click here to find out why I rate VERV ...

Verve Therapeutics (NASDAQ:VERV) stock gains as the company wins the FDA fast track designation for VERVE-102, a cholesterol ...

The AI model, called Damo Panda, was designed to detect early-stage pancreatic cancer using deep learning and abdominal CT ...

Arcturus Therapeutics Holdings Inc. ARCT announced that the FDA has granted a Fast Track designation to its self-amplifying mRNA (sa-mRNA) vaccine candidate, ARCT-2304, for active immunization to ...

In addition, in the second half of 2025, Verve remains on track to report the final data for the dose escalation portion of the Heart-2 clinical trial, deliver the opt-in package for the PCSK9 program ...

Shares of Precision BioSciences DTIL rallied 23.8% on Tuesday after the company’s announcement that the FDA has granted Fast Track designation to PBGENE-HBV. This is DTIL’s lead, fully owned ...

Precision BioSciences (DTIL) announced that the FDA has granted fast track designation for PBGENE-HBV, the company’s lead wholly owned in vivo ...

Arcturus Therapeutics Holdings has won U.S. Food and Drug Administration fast-track designation for its ARCT-2304 pandemic flu vaccine candidate.

Verve Therapeutics has won U.S. Food and Drug Administration fast-track designation for its Verve-102 gene-editing drug targeting a cholesterol driver of atherosclerosis.

Emactuzumab has received FDA fast track designation for TGCT treatment, aiding development for conditions lacking effective options. The phase 3 TANGENT trial evaluates emactuzumab, a CSF-1R ...

The regenerative medicine company focused on stem cell-based therapies and products was just granted Fast Track designation by the U.S. Food and Drug Administration for BRTX-100, its developmental ...